The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Tumor-selective catalytic nanomedicine by nanocatalyst delivery
Open accessAbstract
Tumor cells metabolize in distinct pathways compared with most normal tissue cells. The resulting tumor microenvironment would provide characteristic physiochemical conditions for selective tumor modalities. Here we introduce a concept of sequential catalytic nanomedicine for efficient tumor therapy by designing and delivering biocompatible nanocatalysts into tumor sites. Natural glucose oxidase (GOD, enzyme catalyst) and ultrasmall Fe 3 O 4 nanoparticles (inorganic nanozyme, Fenton reaction catalyst) have been integrated into the large pore-sized and biodegradable dendritic silica nanoparticles to fabricate the sequential nanocatalyst. GOD in sequential nanocatalyst could effectively deplete glucose in tumor cells, and meanwhile produce a considerable amount of H 2 O 2 for subsequent Fenton-like reaction catalyzed by Fe 3 O 4 nanoparticles in response to mild acidic tumor microenvironment. Highly toxic hydroxyl radicals are generated through these sequential catalytic reactions to trigger the apoptosis and death of tumor cells. The current work manifests a proof of concept of catalytic nanomedicine by approaching selectivity and efficiency concurrently for tumor therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Intrinsic peroxidase-like activity of ferromagnetic nanoparticles
Gao, L., Zhuang, J., Nie, L., Zhang, J., Zhang, Y., Gu, N., Wang, T., Feng, J., Yang, D., Perrett, S., et al. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.260 · Cited by 7,483
Ultra-large-scale syntheses of monodisperse nanocrystals
Park, J., An, K., Hwang, Y., Park, J.-G., Noh, H.-J., Kim, J.-Y., Park, J.-H., Hwang, N.-M., & Hyeon, T. (2004) · Nature Materials · doi:10.1038/nmat1251 · Cited by 4,076
Cancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
Cited by
Fu, L., Wan, Y., Qi, C., He, J., Li, C., Yang, C., Xu, H., Lin, J., & Huang, P. (2021) · Advanced Materials · doi:10.1002/adma.202006892 · Cited by 820
Polyphenol‐Containing Nanoparticles: Synthesis, Properties, and Therapeutic Delivery
Guo, Y., Sun, Q., Wu, F., Dai, Y., & Chen, X. (2021) · Advanced Materials · doi:10.1002/adma.202007356 · Cited by 650
Zhou, J., Li, M., Hou, Y., Luo, Z., Chen, Q., Cao, H., Huo, R., Xue, C., Sutrisno, L., Hao, L., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b00309 · Cited by 424
Immunomodulation‐Enhanced Nanozyme‐Based Tumor Catalytic Therapy
Xu, B., Cui, Y., Wang, W., Li, S., Lyu, C., Wang, S., Bao, W., Wang, H., Qin, M., Liu, Z., et al. (2020) · Advanced Materials · doi:10.1002/adma.202003563 · Cited by 404
Sonodynamic therapy-derived multimodal synergistic cancer therapy
Xu, M., Zhou, L., Zheng, L., Zhou, Q., Liu, K., Mao, Y., & Song, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.10.037 · Cited by 211
Metadata
- Authors
- Huo, M., Wang, L., Chen, Y., & Shi, J.
- Venue
- Nature Communications
- Published
- 2017-08-25
- Volume
- 8
- Issue
- 1
- Pages
- 357-357
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2747423355
- Cited by
- 1,322
- References
- 8
- FWCI
- 50.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor-selective catalytic nanomedicine by nanocatalyst delivery. https://app.cochat.ai/papers/10.1038/s41467-017-00424-8
- The paper
- Huo, M., Wang, L., Chen, Y., & Shi, J. (2017). Tumor-selective catalytic nanomedicine by nanocatalyst delivery. Nature Communications. https://doi.org/10.1038/s41467-017-00424-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
